WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David P. BonitaDirector2026-04-211,689,189$4.44
$7.50MBuy
David P. BonitaDirector2026-04-211,126,126$4.44
$5.00MBuy
Orbimed Advisors LLCDirector2026-04-211,689,189$4.44
$7.50MBuy
Orbimed Advisors LLCDirector2026-04-211,126,126$4.44
$5.00MBuy
Jane HuangPresident CMO2025-10-043,355$1.47
$4.93kSell
Jane HuangPresident CMO2025-07-043,355$0.79
$2.66kSell

1 of 1

PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC13.70%10,909,256$45.82MInstitution
Baker Bros Advisors LP12.71%10,123,824$42.52MInstitution
Orbimed Advisors LLC12.28%9,776,491$41.06MInsider
David P. Bonita12.28%9,776,491$41.06MInsider
Baker Bros Advisors LP11.62%9,252,951$38.86MInsider
Ra Capital Management LP9.90%7,882,882$33.11MInsider
Krishna Vaddi3.38%2,693,625$11.31MInsider
Kynam Capital Management LP2.00%1,592,551$6.69MInstitution
Vanguard Capital Management LLC1.54%1,230,406$5.17MInstitution
Ecor1 Capital LLC1.19%947,049$3.98MInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD38.64%51.23%Net BuyingNet Buying
AVIR72.84%27.16%Net BuyingNet Buying
RCKT50.53%49.47%Net SellingNet Selling
CNXU0.00%13.76%Net BuyingNet Buying
ZURA53.91%46.09%Net Buying
View Top Biotech Stocks

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 38.64% institutional shareholders, 51.23% Prelude Therapeutics insiders, and 10.13% retail investors. Orbimed Advisors LLC is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 12.28% of the company. Orbimed Advisors LLC's Prelude Therapeutics shares are currently valued at $42.53M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.